A quality and innovation-led CDMO in cell and gene therapy

Jefferies London Healthcare Conference 2024

Dr. Frank Mathias, CEO 19th November 2024



Legal disclaimer


This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the "Securities"). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford Biomedica plc ("OXB" or the "Company") or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.

This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing.




OXB: A leading CDMO with a rich history

Unmatched track record in viral vector manufacturing



Strong growth in CGT pipeline and CDMO end market

AAV will continue to be the driving force in CGT market growth






4



Our transformation to a pure-play cell and gene therapy CDMO

More than 20 workstreams to provide long-term sustainable growth





Strategy supported by a clear mission and vision

Vision

To transform lives through cell and gene therapy

Mission


To enable our clients to deliver life-changing therapies to patients

We are proud to do something life-changing together Our OXB DNA

Strategy

To create a leading global quality and innovation-led CDMO in cell and gene therapy NA





Responsive







Management team with strong CDMO and value creation expertise

Dr. Frank Mathias

Chief Executive Officer (experience: >35 yrs)

Dr. Kyriacos Mitrophanous

Chief Innovation Officer (experience: >25 yrs)

Thierry Cournez

Chief Operating Officer (experience: >25 yrs)

Natalie Walter

General Counsel (experience: >25 yrs)

Dr. Lucy Crabtree

Chief Financial Officer (experience: >20 yrs)

Dr. Sebastien Ribault

Chief Business Officer (experience: >25 yrs)

Lisa Doman

Chief People Officer (experience: >15 yrs)


Dr. Sabine Sydow

Chief of Staff (experience: >25 yrs)



Our experience and capabilities

Extensive track-record and best-in-class capabilities, accelerating access to lifechanging therapies






Global footprint for greater flexibility


State-of-the-art facilities located within close proximity to our clients

With our global network, we cover the entire value chain of our clients' vector, from development to release:




Significant increase in commercial opportunities since 2022

Business pipeline is maturing and well balanced between existing and new clients



Risk-adjusted pipeline value in \$m

Total opportunities weighted by the probability of success




Significant increase in pipeline value since 2022


Healthy risk-adjusted pipeline underpins 2025 revenue

Note: Pipeline includes commercial value of all identified business opportunities. (1) September 2024 data as per the H1 2024 financial results release.

Risk-adjusted pipeline revenue split

% of pipeline revenue coming from new clients vs existing clients From 154 risk-adjusted pipeline programmes







Diversified and maturing portfolio of client programmes

Number of late-stage & commercial programmes continues to grow

Client programmes by type/phase:



(1) Excludes AstraZeneca COVID-19 vaccine manufacturing, which ended in 2022. PAD: Process and Analytical Development

Benefits to our clients:

11


Why do we win?

Cutting-edge innovation to help tackle complex problems efficiently and quickly

		LentiVector [®] platform	inAAVate™ platform	Adenovirus platform
S	Strong track record	 25+ years of experience with 10+ years in GMP manufacturing 320+ GMP batches successfully released in last 10 years 	 8+ years of experience 50+ GMP batches successfully released in 2 years 	 Delivered 100+ million COVID-19 vaccine doses 70+ GMP batches successfully released
	Fast to GMP	 12 to 16-month timelines available 	 9 to 11-month timelines available 	 12-month timeline
	Cutting edge innovation	 TetraVecta[™] - 4th generation vector; improves quality, potency and packaging capacity 	 Dual-Plasmid system – improves titre and percent full vector 	 Low MOI process reduces virus seeding requirements while maximizing productivity
	Regulatory achievements	 1 successful BLA/MAA submission 24 successful IND submissions 	 6 successful IND submissions 	 1 successful MAA



Unique positioning in an expanding market supports high revenue growth



(1) As at the time of the H1 2024 financial results presentation.

...underpinned by robust operational and commercial drivers

- Continued commercial momentum with total potential revenue pipeline of \$565m and 2024YTD contracted orders of c.£115m¹
- Shift towards advanced-stage programmes provides strong revenue visibility; GMP suite utilisation for 2025 is in excess of 80%
- Cost base right-sized in 2023; ongoing prudent cost discipline
- Strong market opportunity, which OXB has repositioned to capitalise on with "One OXB" strategy



Delivering on our pure-play CDMO growth strategy



High energy management team executing "One OXB" strategy



Strong market demand for OXB's services and expertise



Order book growth due to significant commercial momentum



Strong financial guidance and confidence in future performance



Let's do something life-changing together

A quality and innovation-led CDMO in cell and gene therapy






Appendix



Companies we are supporting

We work with biotech and biopharma companies of all sizes



Our clients include:










H1 2024: Successful transformation of OXB



Robust commercial KPIs

- Underpins expected momentum for H2 2024 and beyond
- ✓ Revenue backlog: c.£120m at 31 Aug 2024
- ✓ Client order value 2024YTD¹: c.£115m → recently signed orders additive
- Transformed financials
- 2023 reorganisation has lowered cost base
- ✓ Operating loss: £(32.2)m (H1 2023: £(50.7)m)
- ✓ Operating EBITDA loss: £(20.3)m (H1 2023: £(33.7)m)

Note: Organic revenue growth excludes acquisition and loss of Homology revenues. Exceeds revenue guidance of >35% CAGR for 2023-2026 (1) As at the time of the H1 2024 financial results presentation.



18

OXB's end-to-end capabilities enable us to be the chosen partner for companies from discovery to commercialisation

Drug development **Pre-clinical** Phase 2 Phase 1 Phase 3 Commercial phases Our Late: ensuring scalability and **Commercial: large scale** Early: developing robust process and delivering solutions clinical material enabling tech transfer commercial supply **Development Feasibility Studies Process Characterisation & Validation** & Analytics **Process Development Analytical Development Pilot Scale Production** Commercial GMP **GMP PPQ** campaigns **Clinical GMP** Size of Up to 50-2,000 Litre 200 to 2,000 Litre 200 to 2,000 Litre Batches¹ **CDMO**

Illustrative OXB Revenue Streams from CDMO Services

\$\$ - \$\$\$

19 Note: Illustration of potential OXB revenue streams throughout the product development process. The timing of OXB revenue recognition from executed contracts will vary depending on agreements with clients 1 Batches dependent on type of therapeutic product and viral vector

\$ - \$\$



\$\$\$

Revenues

ESG 2024 achievements

OXB's ESG strategy is focused on four pillars: People, Community, Environment and Supply Chain



People

Equality, Diversity & Inclusion online training Module launched to all UK employees in July 2024

Three Employee Network groups have raised awareness of newly launched HR policies through celebrating international awareness days with activities and fundraising across all sites



Community

Volunteer day completed removing invasive species from local nature reserve.

Olympic themed events and bake sales took place to raise money for Oxfordshire Mind and Homeless Oxford.

Engagement initiatives with local schools to develop early career paths have taken place



Environment

Scope 1 & 2 near-term carbon reduction science-based target identified as a 42% minimum reduction by 2030 from a 2021 base year

Transition plan for near-term scope 1 & 2 target created with reduction projects identified

Intensity metrics created for energy, water and waste

Complete past UK and US scope 3 data gathered, with French sites underway



Supply Chain

Supplier Code of conduct issued to top 125 suppliers for compliance detailing the overall approach to engagement and expected standards

>80% of UK suppliers responded and confirmed so far



Definitions

BLA/MA submission

Biologics License Application submission and Marketing Authorisation submission respectively.

E2E

End-to-end

GxP, GMP, GCP, GLP

GxP is a general term for Good (Anything) Practice. GMP, GCP and GLP are the practices required to conform to guidelines laid down by relevant agencies for manufacturing, clinical and laboratory activities.

IND submission

An Investigational New Drug Application is a request submitted by a Sponsor to the FDA to enable the Sponsor to conduct clinical trials.

Operating EBITDA

Operating EBITDA (Earnings Before Interest, Tax, Depreciation, Amortisation, Impairment, revaluation of investments and assets at fair value through profit and loss, and Share Based Payments) is a non-GAAP measure often used as a surrogate for operational cash flow as it excludes from operating profit or loss all non-cash items, including the charge for share-based payments.

Orders

Contracted value of client orders represent the value of customer orders for which the customer has signed a financial commitment, whereby any changes to agreed values will be subject to either change orders or cancellation fees.

PPQ

Process Performance Qualification (PPQ) is a critical step in the manufacturing process of pharmaceutical products that assesses the quality and safety of the drug product.

Revenue backlog

Revenue backlog represents ordered CDMO revenues available to earn. It is calculated on a cumulative basis by adding new contracted client orders less the value of revenues already recognised or no longer available after project scope adjustments or cancellations.



Contact us

Oxford Biomedica plc Windrush Court Transport Way Oxford OX4 6LT

Lucy Crabtree Chief Financial Officer

Sophia Bolhassan Head of Investor Relations

IR@oxb.com

www.oxb.com

